190 related articles for article (PubMed ID: 23610071)
21. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
Chen S; Zhao Y; Shen F; Long D; Yu T; Lin X
Oncol Rep; 2019 Mar; 41(3):2051-2059. PubMed ID: 30628717
[TBL] [Abstract][Full Text] [Related]
22. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
23. Stathmin is dispensable for tumor onset in mice.
D'Andrea S; Berton S; Segatto I; Fabris L; Canzonieri V; Colombatti A; Vecchione A; Belletti B; Baldassarre G
PLoS One; 2012; 7(9):e45561. PubMed ID: 23029098
[TBL] [Abstract][Full Text] [Related]
24. p21/CDKN1A mediates negative regulation of transcription by p53.
Löhr K; Möritz C; Contente A; Dobbelstein M
J Biol Chem; 2003 Aug; 278(35):32507-16. PubMed ID: 12748190
[TBL] [Abstract][Full Text] [Related]
25. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of stathmin/oncoprotein 18 correlates with poorer prognosis and interacts with p53 in oral squamous cell carcinoma.
Ma HL; Jin SF; Tao WJ; Zhang ML; Zhang ZY
J Craniomaxillofac Surg; 2016 Oct; 44(10):1725-1732. PubMed ID: 27591090
[TBL] [Abstract][Full Text] [Related]
27. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway.
Wang X; Ren JH; Lin F; Wei JX; Long M; Yan L; Zhang HZ
Cancer Biol Ther; 2010 Sep; 10(6):632-43. PubMed ID: 20657188
[TBL] [Abstract][Full Text] [Related]
28. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination.
Zhang L; Jin Y; Yang H; Li Y; Wang C; Shi Y; Wang Y
Carcinogenesis; 2019 Dec; 40(12):1492-1503. PubMed ID: 31002112
[TBL] [Abstract][Full Text] [Related]
29. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
30. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.
Feng W; Xiaoyan X; Xuan Y; Xiangke L; Zichang Y; Ran Z; Liuxing W; Qingxia F
Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118
[TBL] [Abstract][Full Text] [Related]
31. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
32. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R
Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555
[TBL] [Abstract][Full Text] [Related]
33.
Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
[No Abstract] [Full Text] [Related]
34. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
[TBL] [Abstract][Full Text] [Related]
35. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
Selvendiran K; Tong L; Vishwanath S; Bratasz A; Trigg NJ; Kutala VK; Hideg K; Kuppusamy P
J Biol Chem; 2007 Sep; 282(39):28609-28618. PubMed ID: 17684018
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction.
Ahn J; Murphy M; Kratowicz S; Wang A; Levine AJ; George DL
Oncogene; 1999 Oct; 18(43):5954-8. PubMed ID: 10557083
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of the intercellular adhesion molecule-2 gene as a novel p53 target.
Sasaki Y; Tamura M; Takeda K; Ogi K; Nakagaki T; Koyama R; Idogawa M; Hiratsuka H; Tokino T
Oncotarget; 2016 Sep; 7(38):61426-61437. PubMed ID: 27556181
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53.
Lu P; Vander Mause ER; Redd Bowman KE; Brown SM; Ahne L; Lim CS
J Ovarian Res; 2019 May; 12(1):45. PubMed ID: 31092272
[TBL] [Abstract][Full Text] [Related]
39. Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18-->e mutation in leukemic cells.
Holmfeldt P; Brännström K; Stenmark S; Gullberg M
Mol Biol Cell; 2006 Jul; 17(7):2921-30. PubMed ID: 16624860
[TBL] [Abstract][Full Text] [Related]
40. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
